Rare Diseases Today—April 2, 2026

This week’s Rare Diseases update highlights regulatory approvals, late-stage clinical data, policy leadership changes, and continued momentum in orphan drug development.

In Today’s Newsletter

Dive deeper

🧠 AVLAYAH approved in Hunter syndrome [1] [US • 25 Mar 2026]

https://www.globenewswire.com/news-release/2026/03/25/3262412/0/en/Denali-Therapeutics-Announces-U-S-FDA-Approval-of-AVLAYAH-tividenofusp-alfa-eknm-for-Treatment-of-Hunter-Syndrome-MPS-II.html
Context: AVLAYAH (Denali Therapeutics; tividenofusp alfa-eknm) is an enzyme replacement therapy for neurologic manifestations of Hunter syndrome (MPS II) in presymptomatic or symptomatic pediatric patients weighing at least 5 kg before advanced neurologic impairment.
Key point: U.S. FDA granted accelerated approval based on cerebrospinal fluid heparan sulfate reduction, with a 91% reduction by week 24 reported in Phase 1/2 and 93% (41/44) reaching the range seen in individuals without Hunter syndrome.
Implication: May influence prescriber choice and payer reviews pending full data.

🦴 Efzimfotase alfa posts Phase III HPP results [2] [Global • 31 Mar 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/efzimfotase-alfa-demonstrated-positive-results-global-phase-iii-clinical-programme-hypophosphatasia.html
Context: Efzimfotase alfa (Alexion, AstraZeneca Rare Disease; ALXN1850) was studied across three Phase III trials in 196 patients across 22 countries, spanning pediatric, adolescent, and adult hypophosphatasia (HPP).
Key point: MULBERRY met its primary endpoint in treatment-naïve children, CHESTNUT supported safety and maintenance of benefit in children switching from Strensiq, and HICKORY missed the primary endpoint in adolescents and adults but showed nominal benefits in fatigue and prespecified paediatric-onset subgroups.
Implication: May influence prescriber choice and payer reviews pending full data.

🏛️ NORD expands policy leadership [3] [US • 25 Mar 2026]

https://www.prnewswire.com/news-releases/nord-advances-policy-leadership-with-strategic-appointments-to-strengthen-rare-disease-advocacy-302724180.html
Context: NORD (National Organization for Rare Disorders) appointed Michael J. Beard as Vice President of Federal and Global Public Policy and Cara Tenenbaum as Director of Regulatory Affairs.
Key point: The advocacy group said the appointments are intended to strengthen coordinated legislative and regulatory strategy on behalf of patients, families, and member organizations across the rare disease ecosystem.
Implication: Could inform policy, advocacy, and regulatory engagement across the rare disease field.

☀️ Dersimelagon meets Phase 3 endpoint in EPP and XLP [4] [30 Mar 2026]

https://www.tanabe-pharma.com/en/news/rel_260330/main/0/link/e_rel_260330.pdf
Context: Dersimelagon (Tanabe Pharma; MC1R agonist) was studied in the Phase 3 INSPIRE trial in 165 adults and adolescents aged 12 to 75 years with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP).
Key point: The trial met its primary endpoint, showing a placebo-adjusted least-squares mean increase of 23.19 minutes in average daily sunlight exposure time to first prodromal symptom during weeks 12–16 (p=0.004), with significant secondary outcomes including PGIC and pain events.
Implication: May influence prescriber choice and payer reviews pending full data.

❤️ LOJUXTA gains positive CHMP opinion in pediatric HoFH [5] [EU • 30 Mar 2026]

https://finance.yahoo.com/sectors/healthcare/articles/chiesi-global-rare-diseases-receives-120000689.html
Context: LOJUXTA (Chiesi Global Rare Diseases; lomitapide) is already approved in the EU for adults with homozygous familial hypercholesterolemia (HoFH), and the new opinion covers children aged 5 years and older.
Key point: CHMP recommended approval based on the Phase 3 APH-19 study in 43 pediatric participants, which reported a mean 53.5% LDL-C reduction from baseline at week 24 (p<0.0001), with mostly mild gastrointestinal and hepatic adverse events.
Implication: Introduces competition that may affect pricing and formulary access.

🧬 SGX945 receives EU orphan designation in Behçet’s disease [6] [EU • 26 Mar 2026]

https://www.prnewswire.com/news-releases/soligenix-receives-orphan-drug-designation-from-the-european-commission-for-sgx945-for-the-treatment-of-behcets-disease-302725591.html
Context: SGX945 (Soligenix; dusquetide) received orphan drug designation from the European Commission after a positive recommendation from the EMA Committee for Orphan Medicinal Products.
Key point: Soligenix said the designation follows recently published Phase 2a results showing biological efficacy and safety in Behçet’s disease, and adds to prior U.S. orphan and fast track designations.
Implication: Signals pipeline investment and modality expansion.

🔬 DF-003 receives U.S. orphan designation in ROSAH syndrome [7] [US • 27 Mar 2026]

https://www.biospace.com/press-releases/drug-farm-announces-u-s-fda-orphan-drug-designation-for-df-003-for-the-treatment-of-rosah-syndrome
Context: DF-003 (Drug Farm) is an investigational small molecule ALPK1 inhibitor for ROSAH syndrome, a rare autoinflammatory disease with no approved disease-modifying therapies.
Key point: U.S. FDA granted orphan drug designation for DF-003, and the company said ongoing studies are evaluating safety, pharmacokinetics, pharmacodynamic biomarkers, and efficacy parameters.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Denali’s AVLAYAH approval gives Hunter syndrome a new FDA-approved option aimed at neurologic disease, not only peripheral manifestations. [1]
Alexion’s efzimfotase alfa dataset broadens the HPP evidence base, but also highlights how treatment effect may vary by age and disease onset. [2]
Tanabe’s dersimelagon result could reshape the EPP and XLP landscape by advancing an oral late-stage option for light intolerance. [4]
Chiesi, Soligenix, and Drug Farm each moved programs forward through European or U.S. regulatory pathways, reinforcing continued investment in rare disease development. [5] [6] [7]
NORD’s leadership buildout suggests sustained pressure on policy, access, and regulatory issues that affect rare disease drug development and patient support. [3]

📚 View the full Rare Disease archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What is AVLAYAH, and why is it notable?

AVLAYAH (tividenofusp alfa-eknm) is Denali Therapeutics’ enzyme replacement therapy for neurologic manifestations of Hunter syndrome (MPS II). The release describes it as the first FDA-approved biologic designed to cross the blood-brain barrier for this disease, under accelerated approval. [1]

Did efzimfotase alfa fully succeed in Phase III hypophosphatasia studies?

Partly. Alexion reported clear pediatric wins in MULBERRY and supportive switch data in CHESTNUT, while HICKORY in adolescents and adults did not achieve statistical significance on the primary endpoint, though some secondary and subgroup signals were reported. [2]

What did Tanabe Pharma show with dersimelagon in EPP and XLP?

Tanabe said dersimelagon met the Phase 3 INSPIRE primary endpoint and key secondary endpoints, including patient-reported change and fewer pain events. The company also said NDA preparation is in progress. [4]

What does the CHMP opinion mean for LOJUXTA in pediatric HoFH?

For Chiesi’s LOJUXTA (lomitapide), the positive CHMP opinion is a recommendation toward EU label expansion in children aged 5 years and older with HoFH. The company said a European Commission decision was anticipated by 1 Jun 2026. [5]

What do the orphan designations mean for SGX945 and DF-003?

For Soligenix’s SGX945 in Behçet’s disease and Drug Farm’s DF-003 in ROSAH syndrome, orphan designation supports development through incentives and added regulatory support, but it is not a marketing approval. [6] [7]

Why does NORD’s staffing move matter to industry and patient groups?

NORD said Michael J. Beard and Cara Tenenbaum will strengthen federal, global, and regulatory policy capabilities. That matters because advocacy groups often shape legislative priorities, regulatory feedback, and access discussions in rare disease. [3]

Entities / Keywords

AVLAYAH, tividenofusp alfa-eknm, Denali Therapeutics, Hunter syndrome, MPS II, mucopolysaccharidosis type II, TransportVehicle, transferrin receptor, blood-brain barrier
Efzimfotase alfa, ALXN1850, Alexion, AstraZeneca Rare Disease, hypophosphatasia, HPP, MULBERRY, CHESTNUT, HICKORY, Strensiq, asfotase alfa
NORD, National Organization for Rare Disorders, Michael J. Beard, Cara Tenenbaum, rare disease advocacy, regulatory affairs
Dersimelagon, Tanabe Pharma, EPP, erythropoietic protoporphyria, XLP, X-linked protoporphyria, INSPIRE, MC1R
LOJUXTA, lomitapide, Chiesi Global Rare Diseases, CHMP, EMA, HoFH, homozygous familial hypercholesterolemia, APH-19
SGX945, dusquetide, Soligenix, Behçet’s disease, European Commission, COMP, orphan drug designation
DF-003, Drug Farm, ALPK1, ROSAH syndrome, orphan drug designation, autoinflammatory disease